Enapotamab vedotin (previously referred to as HuMax-AXL-ADC or AXL-107-MMAE) is a clinical-stage AXL-specific antibody-drug conjugate that was generated by conjugating a human AXL-specific IgG1 with the microtubule-disrupting agent monomethyl auristatin